Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 13, 2023

Health-Related Quality-of-Life Outcomes of Treatment With Sacituzumab Govitecan vs Standard Chemotherapy in Patients With Metastatic TNBC

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
Eur. J. Cancer 2023 Jan 01;178(2023)23-33, S Loibl, D Loirat, SM Tolaney, K Punie, M Oliveira, HS Rugo, A Bardia, SA Hurvitz, AM Brufsky, K Kalinsky, J Cortés, JA O'Shaughnessy, V Dieras, LA Carey, L Gianni, M Gharaibeh, L Preger, S Phan, L Chang, L Shi, MJ Piccart

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading